[Immunotherapy of malignant diseases].
Cancer immunotherapy has been carried out since the early fifties and first involved nonspecific system (BCG, Corynebacterium parvum, levamisole...). More recently, the production of cytokines as interferons or interleukin 2, the introduction of monoclonal antibodies have allowed a new development to cancer immunotherapy. Nevertheless, these new approaches have to be considered as a step in the biological therapy of cancer.
Dorval
T
T
Service de médecine oncologique, institut Curie, Paris, France.
Michon
J
J
Tartour
E
E
Fridman
W H
WH
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000628:therapy; D008545:Melanoma / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D009447:Neuroblastoma / Q000628:therapy
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007376:Interleukin-2; D007372:Interferons